Skip to main content
VALIRX PLC logo

VALIRX PLC — Investor Relations & Filings

Ticker · VAL ISIN · GB00BLH13C52 LEI · 213800VQKB9SJCQDET40 IL Professional, scientific and technical activities
Open in API
Filings indexed 574 across all filing types
Latest filing 2024-11-19 Regulatory Filings
Country GB United Kingdom
Listing IL VAL

About VALIRX PLC

https://www.valirx.com/

ValiRx PLC is a life science company that accelerates the development of therapeutics and diagnostics, with a primary focus on oncology and women's health. The company's business model centers on identifying and progressing promising early-stage scientific discoveries through pre-clinical and clinical development. ValiRx provides scientific, financial, and commercial expertise to translate novel research into clinically validated treatments, aiming to improve patient outcomes in its target therapeutic areas.

Recent filings

Filing Released Lang Actions
Contract Award
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number : 7034M' and is dated 19 November 2024. It details a 'Contract Award' update from ValiRx PLC's subsidiary, Inaphaea, regarding a deal with Amply Discovery Limited. The text explicitly states, 'The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law...'. The closing section confirms the source: 'This information is provided by RNS, the news service of the London Stock Exchange.' This structure—a brief announcement of material, non-financial, or operational news released via the RNS system—fits the definition of a general regulatory announcement that doesn't fit a more specific category like ER, DIV, or DIRS. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (6085 chars) is substantial enough that it is the announcement itself, not just a notice of publication.
2024-11-19 English
First Sale of New Product Line
Regulatory Filings Classification · 1% confidence The document is identified by the RNS Number (5842M) and explicitly states, "This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom." The content is a brief operational update ('First Sale of New Product Line') which is typical for a general regulatory announcement disseminated via the RNS system, rather than a comprehensive report (like 10-K or IR) or a specific event material (like AGM-R or DEF 14A). Since it is a general regulatory announcement that doesn't fit the more specific categories (like DIV, DIRS, or ER), the appropriate fallback category is Regulatory Filings (RNS). The document length is moderate (5432 chars), but its structure is that of a news release distributed through a regulatory feed.
2024-11-18 English
Update on proposed sub-license of VAL201
Regulatory Filings Classification · 1% confidence The document is a short announcement released via RNS (the news service of the London Stock Exchange) on October 30, 2024. It details an update regarding an amendment to a Letter of Intent (LOI) concerning a sub-license agreement for a therapeutic candidate (VAL201). It explicitly mentions that the information constitutes 'inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law'. The text is brief and serves as a general regulatory update rather than a full financial report (like 10-K or IR) or a specific transaction report (like DIRS or POS). Since it is a general regulatory announcement distributed through the official news service (RNS) and doesn't fit precisely into the other specific categories (like ER, DIV, or CT), the most appropriate classification is the general regulatory filing category.
2024-10-30 English
Directorate Change
Board/Management Information Classification · 1% confidence The document is an official announcement disseminated via RNS (Regulatory News Service), indicated by the 'RNS Number' header and the concluding boilerplate text referencing RNS and the London Stock Exchange. The core content explicitly announces the 'resignation of Martin Lampshire as a Non-Executive Director of the Company'. This directly corresponds to the definition of Board/Management Information (MANG). It is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2024-10-18 English
Investor Webinar
Report Publication Announcement Classification · 1% confidence The document is a short announcement (4758 characters) released via RNS (RNS Number : 9690H) from ValiRx Plc. The content explicitly invites shareholders to an 'Investor Webinar' scheduled for a future date (October 21st, 2024) to discuss the CEO's vision and future direction. This is not a full financial report (like 10-K or IR), nor is it a formal declaration of voting results (DVA) or a director's dealing (DIRS). It is an announcement about an upcoming event intended for investors. Since it is a formal regulatory announcement distributed via RNS, and it announces an event rather than containing the full substance of a major report, it fits best under the general 'Regulatory Filings' category (RNS) or potentially as a precursor to an AGM/Investor Presentation. Given the nature of inviting investors to a presentation/Q&A, and its format as a brief regulatory news service release, RNS is the most appropriate general classification, although it strongly relates to investor communication.
2024-10-14 English
Inaphaea Co-Marketing Agreement
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number' and is dated '07 October 2024'. It details a specific business update: the execution of a co-marketing agreement between ValiRx's subsidiary Inaphaea and BioRep. The text explicitly mentions that the information is 'deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law' and concludes with boilerplate text from RNS, the news service of the London Stock Exchange, which acts as a Primary Information Provider. This structure strongly indicates a general regulatory announcement disseminated via the RNS system, rather than a specific financial report (like 10-K, IR, ER) or a formal meeting material (like AGM-R, DEF 14A). Since it is a general regulatory announcement that doesn't fit the more specific categories (like DIRS, DIV, CAP, etc.), the most appropriate fallback category is Regulatory Filings (RNS). The document length (7229 chars) is substantial enough to be the primary announcement itself, not just a brief notice of publication.
2024-10-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.